{"Clinical Trial ID": "NCT00127205", "Intervention": ["INTERVENTION 1:", "- Arm I Zoledronate", "Patients receive zoledronate IV for 15 minutes once a month for 6 months and once every 3 months for 2.5 years.", "zoledronic acid: IV", "INTERVENTION 2:", "Arm II Clodronate", "Patients receive clodronate orally once daily for 35 months.", "Clodronate disodium: oral"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "- Histologically confirmed primary adenocarcinoma of the breast", "Stage I-III of the disease", "No sign of metastatic disease", "\u2022 Must have had a lumpectomy or total mastectomy for a primary disease in the last 12 weeks, or have completed chemotherapy in the last 8 weeks", "Axillary evaluation by institutional standards", "Currently, receive or plan standard adjuvant systemic treatment including chemotherapy, hormone therapy or combined chemotherapy/hormonal therapy for breast cancer", "Patients who are at low risk of recurrence of the disease and for whom adjuvant systemic treatment will not be prescribed are not eligible.", "Patients receiving only biological agents or local radiation therapy (without chemotherapy and/or hormone therapy) are not eligible.", "Other treatments are permitted, including radiotherapy and biological agents (e.g., trastuzumab [Herceptin^\u00ae], bevacizumab or hematopoietic growth factors).", "\u2022 Neoadjuvant or hormonal therapy alone is permitted provided that entry into the study takes place 12 weeks after completion of the operation.", "Patients suffering from skeletal pain are eligible provided that bone analysis and/or roentgenological examination are negative for metastatic diseases.", "- Suspicious observations should be confirmed as benign by X-ray, MRI or biopsy.", "- Hormonal receptor status:", "Unspecified", "CHARACTERISTICS OF PATIENTS:", "Age", "- 18 years and over", "Gender", "Women", "Status of menopause", "Unspecified", "State of play", "- Zubrod 0-2", "Life expectancy", "Unspecified", "Haematopoietic", "Unspecified", "Hepatic", "Unspecified", "Renal", "Creatinine 2 times higher than normal", "creatinine clearance 30 mL/min", "No renal impairment", "Other", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective contraception", "No history of esophageal rigor or motility disorders", "A gastroesophageal reflux allowed", "No other malignancy in the last 5 years, except for skin cancer of adequately treated basal or squamous cells, in situ cervix carcinoma, or stage I or II cancer adequately treated for complete remission", "THERAPE PRIOR CONCURENT:", "Biological therapy", "Previous or authorized hematopoietic growth factors", "Therapies targeted by HER-2 are allowed.", "Antiangiogenics authorised", "- Chemotherapy", "See Disease Characteristics", "Endocrinotherapy", "See Disease Characteristics", "Radiotherapy", "A simultaneous radiotherapy in the breast, chest wall or lymph node is permitted at the discretion of the treating physician.", "Surgery", "See Disease Characteristics", "Other", "\u2022 Prior treatment with neoadjuvant is permitted", "Previous bisphosphonates for bone density are allowed", "No other concomitant bisphosphonate as an adjuvant treatment or for the treatment of osteoporosis", "No concurrent listing in clinical trials with bone density as an evaluation criterion", "\u2022 Simultaneous inclusion in any other locoregional or systemic breast cancer therapy study (including cooperative group studies) is permitted"], "Results": ["Performance measures:", "\u2022 Disease-free survival", "Patients who have not experienced a recurrence of disease are censored at their last contact date. The result of disease-free survival will be presented as a 5-year survival rate.", "Timeline: Disease assessments are conducted every 6 months for 5 years and each year for 5 years or until death or recurrence", "Results 1:", "Title of arm/group: Arm I Zoledronate", "Description of the arm/group: Patients receive zoledronate IV for 15 minutes once a month for 6 months, then once every 3 months for 2.5 years.", "zoledronic acid: IV", "Total number of participants analysed: 2231", "Type of measurement: Number", "Unit of measure: percentage of participants analysed 88 (87 to 90)", "Results 2:", "Title of arm/group: Arm II Clodronate", "Description of arm/group: Patients receive oral clodronate once daily for 35 months.", "Clodronate disodium: oral", "Total number of participants analysed: 2235", "Type of measurement: Number", "Unit of measure: percentage of participants analysed 88 (86-89)"], "Adverse Events": ["Undesirable Events 1:", "Total: 21/2125 (0.99%)", "- Febrile neutropenia 0/2125 (0.00 %)", "Hemoglobin 0/2125 (0.00 %)", "- Cardiac General-Others 0/2125 (0.00 %)", "- Cardiac ischemia/infarction 1/2125 (0.05%)", "Abnorm/AV conduction block - Sick sinus syndrome 0/2125 (0.00 %)", "- Left ventricular diastolic dysfunction 0/2125 (0.00 %)", "- Left ventricular systolic dysfunction 0/2125 (0.00 %)", "Pain - Cardiac/Heart 0/2125 (0.00 %)", "Adverse Events 2:", "Total: 190/2186 (8.69 per cent)", "- Febrile neutropenia 3/2186 (0.14%)", "Hemoglobin 3/2186 (0.14%)", "2/2186 (0.09%)", "1/2186 (0.05%)", "Abnorm/AV conduction block - Sick sinus syndrome 1/2186 (0.05%)", "Left ventricular diastolic dysfunction 3/2186 (0.14%)", "Left ventricular systolic dysfunction 1/2186 (0.05%)", "Cardiac/heart pain 3/2186 (0.14%)"]}